Is Carl Zeiss AG profitable in 2026?

Yes. ZEISS Group posted €11.896 billion revenue in FY2024/25 (ended 30 Sept 2025), up 9% year over year, with EBIT of €1.552 billion, a 13% margin. H1 FY2025/26 revenue reached €5.841 billion with EBIT of €955 million, though management called segment performance 'highly uneven.'

Could AI replace Carl Zeiss's business?

No. Zeiss's core is atomic-tolerance precision optics manufacturing, including EUV lithography mirrors for ASML, plus regulated medical devices, neither of which AI can produce. Zeiss instead bolts AI onto products, like the ZEN core software suite launched March 2025 and Microscopy Copilot, rather than facing AI disruption.

Is Carl Zeiss doing layoffs in 2026?

Yes, selectively. Carl Zeiss Meditec announced on 14 May 2026 plans to cut up to 1,000 jobs globally over three years under its 'ProfitUp' program targeting €200 million in annual earnings gains by FY2028/29. Separately, Sports Optics is ending analog manufacturing at Wetzlar by end 2026, affecting about 70 roles.

Who owns Carl Zeiss AG?

Carl Zeiss AG is 100% owned by the Carl Zeiss Foundation (Carl-Zeiss-Stiftung), a German science foundation that also owns glassmaker SCHOTT AG. The parent is not publicly traded; only its subsidiary Carl Zeiss Meditec AG trades on Deutsche Börse under ticker AFX, with a market cap around €2.39 billion as of 24 July 2026.

Is Zeiss's biggest rival ASML or Nikon?

Neither is a true rival today. ASML is Zeiss's largest customer and 2017 equity partner (a ~€1 billion investment into Carl Zeiss SMT), holding about 83% of global lithography-machine sales. Nikon tried to compete in immersion lithography optics, sued ASML and Zeiss over patents in 2017, and lost that technical race.

Is joining Carl Zeiss Meditec risky right now?

There is real near-term turbulence: Meditec suspended its FY2025/26 guidance on 22 January 2026, its CEO was terminated for a compliance violation effective 1 January 2026, and up to 1,000 jobs are being cut through FY2028/29. A new CEO, Bronwyn Brophy O'Connor, was named 22 May 2026 to lead the turnaround.

Biotech tools companies · state-owned · Germany

Carl Zeiss AG

zeiss.com ↗

German foundation-owned optics giant, sole maker of ASML's EUV lithography mirrors.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: H1 FY2025/26 results and renewed Meditec guidance, plus new CEO Bronwyn Brophy O'Connor's start

The call

Zeiss's semiconductor optics arm is locked in as ASML's only mirror supplier, while its medical device arm loses ground in China lens pricing and awaits new leadership to steady the business.

Carl Zeiss AG makes precision optical systems, with its biggest profit engine being specialized mirrors that ASML uses in machines that etch computer chips. This business is extremely hard to copy because it requires 180 years of accumulated knowledge, the ability to manufacture at atomic scales, and ASML's deep financial ties to Zeiss, making it nearly impossible for rivals like China's optics makers to replicate. However, Zeiss's future depends almost entirely on one customer (ASML) and whether the world continues buying the expensive chip-making equipment that uses these mirrors. If chipmakers suddenly need less advanced equipment or ASML's growth plans slow down, Zeiss loses its main moneymaker.

Why

AI pressure: None apparent. AI models don't grind atomic-scale mirrors; Zeiss's EUV optics and microscopy hardware sit outside software substitution. Could AI do the core job? Unlikely.

Bigger players: Alcon. Zeiss pulled its bifocal IOL from China's VBP tender in early 2026, ceding volume in that lens category to rivals like Alcon. Could a giant copy it? No, they are blocked.

What protects it. Decades of proprietary EUV mirror design plus ASML's 2017 €1B equity stake lock Zeiss in as the only supplier ASML can use.

What would change this call

Carl Zeiss Meditec issues new FY2025/26 guidance by half-year results in June 2026. Shows whether the Medical Technology slump is stabilizing or deepening.
ASML confirms or cuts its 2027-28 EUV capacity expansion plans in future earnings calls. Would directly signal whether Zeiss's SMT profit engine keeps growing or slows.
Bronwyn Brophy O'Connor's Meditec CEO start date is finalized and ProfitUp job cuts begin rolling out. Indicates whether Meditec's restructuring and cost program are proceeding on schedule.

Key numbers

ZEISS Group revenue €11.896B FY2024/25, up 9% (2025-09-30)
SMT segment sales €2.47B in H1, up 22% YoY (2025-09-30)
Meditec cutting up to 1,000 jobs, targeting €200M savings (2026-05-14)

Named risks

SMT segment concentration on single customer ASML; any EUV roadmap slowdown hits Zeiss's largest profit driver. Severity: high
Meditec guidance suspended since 22 January 2026 with unresolved FY2025/26 outlook. Severity: medium
Execution risk on cutting up to 1,000 Meditec jobs and delivering €200M ProfitUp savings by FY2028/29. Severity: medium
China volume-based procurement pricing pressure hurting Meditec's IOL and ophthalmology revenue. Severity: medium
Leadership disruption after CEO termination for compliance violation, effective 1 January 2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
ASML	contesting	SMT profit engine entirely tied to ASML's single-customer cycle and 2027-28 capacity plans as of Jul 2026
Nikon	gaining on	Nikon sued ASML and Zeiss over immersion lithography patents in 2017 and lost the technical race

Questions people ask

Is Carl Zeiss AG profitable in 2026?: Yes. ZEISS Group posted €11.896 billion revenue in FY2024/25 (ended 30 Sept 2025), up 9% year over year, with EBIT of €1.552 billion, a 13% margin. H1 FY2025/26 revenue reached €5.841 billion with EBIT of €955 million, though management called segment performance 'highly uneven.'
Could AI replace Carl Zeiss's business?: No. Zeiss's core is atomic-tolerance precision optics manufacturing, including EUV lithography mirrors for ASML, plus regulated medical devices, neither of which AI can produce. Zeiss instead bolts AI onto products, like the ZEN core software suite launched March 2025 and Microscopy Copilot, rather than facing AI disruption.
Is Carl Zeiss doing layoffs in 2026?: Yes, selectively. Carl Zeiss Meditec announced on 14 May 2026 plans to cut up to 1,000 jobs globally over three years under its 'ProfitUp' program targeting €200 million in annual earnings gains by FY2028/29. Separately, Sports Optics is ending analog manufacturing at Wetzlar by end 2026, affecting about 70 roles.
Who owns Carl Zeiss AG?: Carl Zeiss AG is 100% owned by the Carl Zeiss Foundation (Carl-Zeiss-Stiftung), a German science foundation that also owns glassmaker SCHOTT AG. The parent is not publicly traded; only its subsidiary Carl Zeiss Meditec AG trades on Deutsche Börse under ticker AFX, with a market cap around €2.39 billion as of 24 July 2026.
Is Zeiss's biggest rival ASML or Nikon?: Neither is a true rival today. ASML is Zeiss's largest customer and 2017 equity partner (a ~€1 billion investment into Carl Zeiss SMT), holding about 83% of global lithography-machine sales. Nikon tried to compete in immersion lithography optics, sued ASML and Zeiss over patents in 2017, and lost that technical race.
Is joining Carl Zeiss Meditec risky right now?: There is real near-term turbulence: Meditec suspended its FY2025/26 guidance on 22 January 2026, its CEO was terminated for a compliance violation effective 1 January 2026, and up to 1,000 jobs are being cut through FY2028/29. A new CEO, Bronwyn Brophy O'Connor, was named 22 May 2026 to lead the turnaround.

Timeline

2026-07-24Zeiss announces SMT expansion: second Wetzlar site with ~500 jobs, 25,000+ m2 added at Oberkochen
2026-06-09H1 FY2025/26 results: Group revenue €5.841B, up 1%, EBIT €955M, segment performance 'highly uneven'
2026-05-29Sports Optics to end analog optics manufacturing at Wetzlar by end 2026, ~70 roles affected
2026-05-22Bronwyn Brophy O'Connor named incoming CEO of Carl Zeiss Meditec AG
2026-05-14Meditec announces plan to cut up to 1,000 jobs over three years under ProfitUp program
2026-01-22Carl Zeiss Meditec suspends FY2025/26 financial guidance
2026-01-01Andreas Pecher becomes interim Meditec CEO after Maximilian Foerst's contract terminated
2025-12-17ZEISS Group reports FY2024/25 revenue of €11.896B, up 9%, EBIT €1.552B
2025-04-30ZEISS launches AI-powered Research Data Platform for ophthalmic research at ARVO
2025-03-31ZEN core universal SEM software suite launched for all ZEISS electron microscopes

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE